XENLETA

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug XENLETA contains one active pharmaceutical ingredient (API):

1 Lefamulin UNII HDN0B924X4 - LEFAMULIN ACETATE

Lefamulin is a pleuromutilin antibacterial agent. It inhibits bacterial protein synthesis by interacting with the A- and P- sites of the peptidyl transferase centre (PTC) in the central part of domain V of the 23S rRNA of the 50S ribosomal subunit, preventing correct positioning of the tRNA. Lefamulin is indicated for the treatment of community-acquired pneumonia (CAP) in adults. Read about Lefamulin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XENLETA Solution for injection / Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J01XX12		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XX Other antibacterials
Discover more medicines within J01XX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1824454, 1824465
Country: IT	Agenzia del Farmaco	Identifier(s): 048963019, 048963021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090897, 1090898
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100440180, 100440196
Country: US	FDA, National Drug Code	Identifier(s): 72000-110, 72000-120